CEACAM6 (E7S7Y) Rabbit mAb #85102
- WB
- IHC
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 50-200 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:1600 - 1:6400 |
Storage
For a carrier free (BSA and azide free) version of this product see product #51309.
Protocol
Specificity / Sensitivity
CEACAM6 (E7S7Y) Rabbit mAb recognizes endogenous levels of total CEACAM6 protein. This antibody does not cross-react with CEACAM1, 5, or 8 proteins.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys246 of human CEACAM6 protein.
Background
Carcinoembryonic antigen (CEA)-related cell adhesion molecule 6 (CEACAM6) is a member of the CEA-related cell adhesion molecule (CEACAM) family (1). CEACAMs bind to themselves and other family members to carry out numerous cellular functions, including proliferation, signaling, differentiation, tumor suppression, and survival (2). CEACAM6 is a single-chain, glycosylphosphatidylinositol (GPI)-anchored, highly glycosylated protein that is normally expressed on epithelial cells and granulocytes (3,4). CEACAM6 mediates homophilic and heterophilic cell adhesion with other CEA-related cell adhesion molecules, such as CEACAM5 and CEACAM8 (3-6). Heterophilic interaction with CEACAM8 occurs in activated neutrophils (7), and plays a role in neutrophil adhesion to cytokine-activated endothelial cells (4). High levels of CEACAM6 expression are also observed in several different cancers (8-10). In cancer, CEACAM6 promotes tumor progression, migration, invasion, and metastasis, and therefore is considered a target for therapeutic intervention (11-13).
- Kuespert, K. et al. (2006) Curr Opin Cell Biol 18, 565-71.
- Bonsor, D.A. et al. (2015) Proc Natl Acad Sci U S A 112, 13561-6.
- Kuroki, M. et al. (2001) J Leukoc Biol 70, 543-50.
- Kuijpers, T.W. et al. (1992) J Cell Biol 118, 457-66.
- Oikawa, S. et al. (1989) Biochem Biophys Res Commun 164, 39-45.
- Oikawa, S. et al. (1991) J Biol Chem 266, 7995-8001.
- Skubitz, K.M. et al. (1996) J Leukoc Biol 60, 106-17.
- Duxbury, M.S. et al. (2004) Br J Cancer 91, 1384-90.
- Schölzel, S. et al. (2000) Am J Pathol 156, 595-605.
- Beauchemin, N. and Arabzadeh, A. (2013) Cancer Metastasis Rev 32, 643-71.
- Zhang, Y. et al. (2014) Acta Biochim Biophys Sin (Shanghai) 46, 283-90.
- Blumenthal, R.D. et al. (2005) Cancer Res 65, 8809-17.
- Ru, G.Q. et al. (2017) Oncotarget 8, 83673-83683.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.